Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gal Markel

Showing results (111-120 of 137) with videos related to

Pageof 14
Sort By:
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 10, 2011
Establishment and large-scale expansion of minimally cultured "young" tumor infiltrating lymphocytes for adoptive transfer therapyOrit Itzhaki, Einat Hovav, Yaara Ziporen, et al.
Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals|August 2, 2013
A comparative analysis of total serum miRNA profiles identifies novel signature that is highly indicative of metastatic melanoma: a pilot studyEyal Greenberg, Michal J Besser, Eytan Ben-Ami, et al.
Cancer Immunology Research|October 3, 2018
Clinical Significance of Pancreatic Atrophy Induced by Immune-Checkpoint Inhibitors: A Case-Control StudyYael Eshet, Erez Nissim Baruch, Ronnie Shapira-Frommer, et al.
Oncotarget|September 5, 2015
A novel immune resistance mechanism of melanoma cells controlled by the ADAR1 enzymeGilli Galore-Haskel, Yael Nemlich, Eyal Greenberg, et al.
Cancer Immunology, Immunotherapy : CII|July 28, 2009
Systemic dysregulation of CEACAM1 in melanoma patientsGal Markel, Rona Ortenberg, Rachel Seidman, et al.
Neoplasia (New York, N.Y.)|June 17, 2014
CEACAM1 promotes melanoma cell growth through Sox-2Rona Ortenberg, Gilli Galore-Haskel, Ilanit Greenberg, et al.
Journal for Immunotherapy of Cancer|March 11, 2020
Head-to-head comparison of in-house produced CD19 CAR-T cell in ALL and NHL patientsOrit Itzhaki, Elad Jacoby, Abraham Nissani, et al.
Cancer Immunology, Immunotherapy : CII|September 11, 2019
TNFSF4 (OX40L) expression and survival in locally advanced and metastatic melanomaJason Roszik, Ettai Markovits, Paula Dobosz, et al.
Nature Immunology|April 12, 2005
Inhibition of the NKp30 activating receptor by pp65 of human cytomegalovirusTal I Arnon, Hagit Achdout, Ofer Levi, et al.
Cancer Immunology Research|April 19, 2023
MYC Induces Immunotherapy and IFNγ Resistance Through Downregulation of JAK2Ettai Markovits, Ortal Harush, Erez N Baruch, et al.
Pageof 14

Showing results (111-120 of 137) with videos related to

Sort By:
Pageof 14
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 10, 2011
Establishment and large-scale expansion of minimally cultured "young" tumor infiltrating lymphocytes for adoptive transfer therapyOrit Itzhaki, Einat Hovav, Yaara Ziporen, et al.
Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals|August 2, 2013
A comparative analysis of total serum miRNA profiles identifies novel signature that is highly indicative of metastatic melanoma: a pilot studyEyal Greenberg, Michal J Besser, Eytan Ben-Ami, et al.
Cancer Immunology Research|October 3, 2018
Clinical Significance of Pancreatic Atrophy Induced by Immune-Checkpoint Inhibitors: A Case-Control StudyYael Eshet, Erez Nissim Baruch, Ronnie Shapira-Frommer, et al.
Oncotarget|September 5, 2015
A novel immune resistance mechanism of melanoma cells controlled by the ADAR1 enzymeGilli Galore-Haskel, Yael Nemlich, Eyal Greenberg, et al.
Cancer Immunology, Immunotherapy : CII|July 28, 2009
Systemic dysregulation of CEACAM1 in melanoma patientsGal Markel, Rona Ortenberg, Rachel Seidman, et al.
Neoplasia (New York, N.Y.)|June 17, 2014
CEACAM1 promotes melanoma cell growth through Sox-2Rona Ortenberg, Gilli Galore-Haskel, Ilanit Greenberg, et al.
Journal for Immunotherapy of Cancer|March 11, 2020
Head-to-head comparison of in-house produced CD19 CAR-T cell in ALL and NHL patientsOrit Itzhaki, Elad Jacoby, Abraham Nissani, et al.
Cancer Immunology, Immunotherapy : CII|September 11, 2019
TNFSF4 (OX40L) expression and survival in locally advanced and metastatic melanomaJason Roszik, Ettai Markovits, Paula Dobosz, et al.
Nature Immunology|April 12, 2005
Inhibition of the NKp30 activating receptor by pp65 of human cytomegalovirusTal I Arnon, Hagit Achdout, Ofer Levi, et al.
Cancer Immunology Research|April 19, 2023
MYC Induces Immunotherapy and IFNγ Resistance Through Downregulation of JAK2Ettai Markovits, Ortal Harush, Erez N Baruch, et al.
Pageof 14